This supplement to The American Journal of Managed Care includes information on best practices in diabetes management, including the effects of drug benefit design and quality of care measures in improving diabetes care.
Faculty
Lawrence Blonde, MD, FACP, FACE
Director
Ochsner Diabetes Clinical Research Unit
Ochsner Clinic Foundation
New Orleans, Louisiana
John J. Mahoney, MD
Corporate Medical Director
Pitney Bowes
Stamford, Connecticut
Patrick J. O'Connor, MD, MPH
Senior Clinical Investigator
HealthPartners Research Foundation
Minneapolis, Minnesota
JoAnn M. Sperl-Hillen, MD
Clinical Investigator
HealthPartners Research Foundation
Minneapolis, Minnesota
Disclosure Statement
It is the policy of The American Journal of Managed Care to have all faculty who participate in programs sponsored by corporate organizations disclose any real or apparent conflicts of interest.
The following participants have declared no financial affiliations with corporate organizations:
Patrick J. O'Connor, MD, MPH
JoAnn M. Sperl-Hillen, MD
These participants have declared the following affiliations with corporate organizations:
Lawrence Blonde, MD, FACP, FACE Grant/Research Support From/Consultant For/Honoraria From:
Amylin Pharmaceuticals
AstraZeneca
Aventis
BD
Bristol-Myers Squibb
Eli Lilly and Company
EMD
GlaxoSmithKline
Merck & Co, Inc
Novartis Pharmaceuticals Corporation
Novo Nordisk
Pfizer
Sanofi-Aventis
Consultant For/Honoraria From:
Abbott Laboratories
LifeScan
Merck/Schering-Plough
Honoraria From:
Takeda Pharmaceuticals of America
Wyeth
John J. Mahoney, MD
Initial work on the predictive modeling discussed in his article was funded by a grant from Eli Lilly and Company.
Signed disclosures are on file at the offices of The American Journal of Managed Care, Jamesburg, New Jersey.
This publication was made possible by funding from GlaxoSmithKline.
The contents of this supplement may include information regarding the use of products that may be inconsistent with or outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.
| |
